Fatty liver is one of the conditions that are being rampantly reported, but the symptoms remain unknown to the patients. The ...

The non-alcoholic steatohepatitis (NASH) clinical trials market is estimated to generate a market size of USD 2.96 billion in ...

Metabolic dysfunction–associated steatohepatitis (MASH) is the new term for non-alcoholic steatohepatitis (NASH). There are several reasons for the name change.

Altimmune stock took a huge hit after its liver disease drug, pemvidutide, failed to show strong results in reducing fibrosis ...

In short, fatty liver might seem harmless at first, but ignoring it can lead to life-threatening problems like cirrhosis, ...

Fatty liver disease is a common health issue. It is often linked to weight and lifestyle. Early detection is key to prevent ...

Non-alcoholic fatty liver disease (NAFLD) is increasingly common due to sedentary lifestyles and poor dietary habits. Here ...

Hamid O, Eltelbany A, Mohammed A, Alsabbagh Alchirazi K, Trakroo S, Asaad I. The epidemiology of non-alcoholic steatohepatitis (NASH) in the United States between 2010-2020: a population-based study.

In an opinion article, investigators argue that gene therapies may not achieve their full potential if the innate inflammation in Duchenne muscular dystrophy is not effectively managed.

One of the most common causes of liver disease besides alcohol is non-alcoholic fatty liver disease (NAFLD). This happens ...

The global non-alcoholic steatohepatitis clinical trials market is on a significant upward trajectory, projected to grow from USD 2,964.4 million in 2025 to USD 5,806.8 million by 2035, according to ...

The most deadly yet underdiagnosed condition by doctors: Non-Alcoholic Fatty Liver Disease. 1 in 3 adults have it and it ...